4D Molecular Therapeutics, Inc. Financing Cash Flow
4D Molecular Therapeutics, Inc. (FDMT) reported Financing Cash Flow of $53.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $42.34M, a 4811.72% increase year-over-year.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $11.48M.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $111.98M, a 18532.61% increase year-over-year.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $116.00K, a 79.58% decline year-over-year.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $112.96M, a 66.51% decline from fiscal 2024.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $337.25M, a 115.04% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $156.83M, a 4983.70% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $3.08M, a 97.39% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $53.82M 10-Q · filed 2026-08-13 | $165.81M derived: sum of 3 quarters · filed 2026-08-13 | $165.92M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $11.48M 10-Q · filed 2026-05-07 | $123.47M derived: sum of 2 quarters · filed 2026-05-07 | $123.58M derived: sum of 3 quarters · filed 2026-05-07 | $124.44M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $111.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $112.10M derived: sum of 2 quarters · filed 2026-03-18 | $112.96M derived: sum of 3 quarters · filed 2026-08-13 | $112.96M 10-K · filed 2026-03-18 |
| 2025-09-30 | $116.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $978.00K derived: sum of 2 quarters · filed 2026-08-13 | $978.00K 10-Q · filed 2025-11-10 | $1.58M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $862.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $862.00K 10-Q · filed 2026-08-13 | $1.46M derived: sum of 3 quarters · filed 2026-08-13 | $2.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $601.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.17M derived: sum of 3 quarters · filed 2026-05-07 | $18.42M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $601.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $1.17M derived: sum of 2 quarters · filed 2026-03-18 | $18.42M derived: sum of 3 quarters · filed 2026-03-18 | $337.25M 10-K · filed 2026-03-18 |
| 2024-09-30 | $568.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $17.82M derived: sum of 2 quarters · filed 2025-11-10 | $336.65M 10-Q · filed 2025-11-10 | $341.41M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $17.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $336.08M 10-Q · filed 2025-08-11 | $340.84M derived: sum of 3 quarters · filed 2025-08-11 | $351.40M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $318.83M 10-Q · filed 2025-05-08 | $323.59M derived: sum of 2 quarters · filed 2025-05-08 | $334.15M derived: sum of 3 quarters · filed 2025-05-08 | $464.67M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $4.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $15.32M derived: sum of 2 quarters · filed 2025-02-28 | $145.84M derived: sum of 3 quarters · filed 2025-02-28 | $156.83M 10-K · filed 2025-02-28 |
| 2023-09-30 | $10.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $141.08M derived: sum of 2 quarters · filed 2024-11-13 | $152.07M 10-Q · filed 2024-11-13 | $154.12M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $130.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $141.51M 10-Q · filed 2024-08-08 | $143.56M derived: sum of 3 quarters · filed 2024-08-08 | $144.02M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $10.99M 10-Q · filed 2024-05-09 | $13.04M derived: sum of 2 quarters · filed 2024-05-09 | $13.50M derived: sum of 3 quarters · filed 2024-05-09 | $13.45M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.51M derived: sum of 2 quarters · filed 2024-02-29 | $2.46M derived: sum of 3 quarters · filed 2024-02-29 | $3.08M 10-K · filed 2024-02-29 |
| 2022-09-30 | $460.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $410.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.04M 10-Q · filed 2023-11-09 | $117.18M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $579.00K 10-Q · filed 2023-08-09 | $116.72M derived: sum of 3 quarters · filed 2023-08-09 | $118.69M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $629.00K 10-Q · filed 2023-05-11 | $116.77M derived: sum of 2 quarters · filed 2023-05-11 | $118.75M derived: sum of 3 quarters · filed 2023-05-11 | $119.56M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $116.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $118.12M derived: sum of 2 quarters · filed 2023-03-15 | $118.94M derived: sum of 3 quarters · filed 2023-03-15 | $118.09M 10-K · filed 2023-03-15 |
| 2021-09-30 | $1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.80M derived: sum of 2 quarters · filed 2022-11-08 | $1.95M 10-Q · filed 2022-11-08 | $207.93M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $820.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$27.00K 10-Q · filed 2022-08-11 | $205.95M derived: sum of 3 quarters · filed 2022-08-11 | $206.85M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$847.00K 10-Q · filed 2022-05-12 | $205.13M derived: sum of 2 quarters · filed 2022-05-12 | $206.03M derived: sum of 3 quarters · filed 2022-05-12 | $278.52M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $205.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $206.88M derived: sum of 2 quarters · filed 2022-03-28 | $279.37M derived: sum of 3 quarters · filed 2022-03-28 | $278.98M 10-K · filed 2022-03-28 |
| 2020-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $73.39M derived: sum of 2 quarters · filed 2021-11-10 | $73.00M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $72.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $72.11M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$389.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$2.19M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |